Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 8, 2010, Pages 1145-1154

  Arai, Sally ^a   Letsinger, Renee ^a   Wong, Ruby M ^a   Johnston, Laura J ^a   Laport, Ginna G ^a   Lowsky, Robert ^a   Miklos, David B ^a   Shizuru, Judith A ^a   Weng, Wen Kai ^a   Lavori, Philip W ^a   Blume, Karl G ^a   Negrin, Robert S ^a   Horning, Sandra J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autologous; Hodgkin lymphoma; Transplantation

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; GEMCITABINE; NAVELBINE;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CLINICAL TRIAL; COUGHING; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART TAMPONADE; HEMORRHAGIC CYSTITIS; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RASH; RECURRENT HODGKIN LYMPHOMA; REFRACTORY HODGKIN LYMPHOMA; SKIN TOXICITY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; VINBLASTINE; YOUNG ADULT;

EID: 77954313319     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.02.022     Document Type: Article

References (61)

1. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993, 341:1051-1054.
2. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 2002, 359:2065-2071.
3. Velasquez W.S., Cabanillas F., Salvador P., et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988, 71:117-122.
4. Josting A., Rudolph C., Reiser M., et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002, 13:1628-1635.
5. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001, 97:616-623.
6. Baetz T., Belch A., Couban S., et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003, 14:1762-1767.
7. Bartlett N.L., Niedzwiecki D., Johnson J.L., et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007, 18:1071-1079.
8. Josting A., Rudolph C., Mapara M., et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005, 16:116-123.
9. Glossmann J.-P., Josting A., Pfistner B., Paulus U., Engert A. A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). Ann Hematol 2002, 81:424-429.
10. Reece D.E., Barnett M.J., Connors J.M., et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991, 9:1871-1879.
11. Nademanee A., O'Donnell M.R., Snyder D.S., et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995, 85:1381-1390.
12. Horning S.J., Chao N.J., Negrin R.S., et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997, 89:801-813.
13. Wheeler C., Eickhoff C., Elias A., et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997, 3:98-106.
14. Frankovich J., Donaldson S.S., Lee Y., et al. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic lung injury syndromes. Biol Blood Marrow Transplant 2001, 7:49-57.
15. Stiff P.J., Unger J.M., Forman S.J., et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003, 9:529-539.
16. Yuen A.R., Rosenberg S.A., Hoppe R.T., Halpern J.D., Horning S.J. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997, 89:814-822.
17. Cao T.M., Negrin R.S., Stockerl-Goldstein K.E., et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000, 6:387-394.
18. Reece D.E., Nevell T.J., Sayegh A., et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant 1999, 23:1131-1138.
19. Stuart M.J., Chao N.S., Horning S.J., et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biol Blood Marrow Transplant 2001, 7:552-560.
20. Benekli M., Smiley S.L., Younis T., et al. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hemtopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant 2008, 41:613-619.
21. Takvorian T., Parker L.M., Hochberg F.H., Canellos G.P. Autologous bone-marrow transplantation: host effects of high-dose BCNU. J Clin Oncol 1983, 1:610-620.
22. Wheeler C., Antin J.H., Churchill W.H., et al. Cyclophosphamide, carmustine, etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990, 8:648-656.
23. Kalaycioglu M., Kavuru M., Tauson L., Bolwell B. Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carumustine (BCNU). Chest 1995, 107:482-487.
24. Horwitz S.M., Negrin R.S., Blume K.G., et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004, 103:777-783.
25. Jagannath S., Dicke K.A., Armitage J.O., et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986, 104:163-168.
26. Borchmann P., Schnell R., Diehl V., Engert A. New drugs in the treatment of Hodgkin's disease. Ann Oncol 1998, 9(Suppl 5):S103-S108.
27. Santoro A., Bredenfeld H., Devizzi L., et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000, 18:2615-2619.
28. Zinzani P.L., Bendandi M., Stefoni V., et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000, 85:926-929.
29. Lucas J.B., Horwitz S.M., Horning S.J., Sayegh A. Gemcitabine is active in relapsed Hodgkin's disease. J Clin Oncol 1999, 17:2627-2628.
30. Devizzi L., Santoro A., Bonfanti V., Viviani S., Bonadonna G. Vinorelbine: a new promising drug in Hodgkin's disease. Leukemia Lymphoma 1996, 22:409-414.
31. Bonfante V., Viviani S., Santoro A., et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol 1998, 103:533-535.
32. Rule S., Tighe M., Davies S., Johnson S. Vinorelbine in the treatment of lymphoma. Hematol Oncol 1998, 16:101-105.
33. Grunewald R., Kantarjian H., Du M., et al. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992, 10:406-413.
34. Mani S., Kugler J.W., Knost J.A., et al. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest New Drugs 1998, 16:275-278.
35. Brand R., Capadano M., Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 1997, 15:331-341.
36. Hainsworth J.D., Burris H.A., Litchy S., et al. Gemcitabine and vinorelbine in the second-line treatment of non-small cell lung carcinoma patients: a Minnie Pearl Cancer Research Network phase II trial. Cancer 2000, 88:1353-1358.
37. Lorusso V., Carpagnano F., Frasci G., et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer. J Clin Oncol 2000, 18:405-411.
38. Delord J.P., Raymond E., Chaouche M., et al. A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. Ann Oncol 2000, 11:73-79.
39. DeLeve L.D., Shulman H.M., McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002, 22:27-42.
40. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
41. Hutchings M., Mikhaeel N.G., Fields P.A., Nunan T., Timothy A.R. Prognostic value of interim FDG-PET after two or 3 cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005, 16:1160-1168.
42. Gallamini A., Hutchings M., Rigacci L., et al. Early interim2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from the Joint Italian-Danish Study. J Clin Oncol 2007, 25:3746-3752.
43. Poen J.C., Hoppe R.T., Horning S.J. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 1996, 36:3-12.
44. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stati Assoc 1958, 53:457-481.
45. Horning S.J. Primary refractory Hodgkin's disease. Ann Oncol 1998, 9(Suppl 5):S97-S101.
46. Lavoie J.C., Connors J.M., Phillips G.L., et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005, 106:1473-1478.
47. Moskowitz A.J., Perales M.A., Kewalramani T., et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009, 146:158-163.
48. Cheng Y.C., Rondon G., Yang Y., et al. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant 2004, 10:794-804.
49. Wadhwa P.D., Fu P., Koc O.N., et al. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Biol Blood Marrow Transplant 2005, 11:13-22.
50. Chien J.W., Madtes D.K., Clark J.G. Pulmonary function testing prior to hematopoietic stem cell transplantation. Bone Marrow Transplant 2005, 35:429-435.
51. Josting A., Franklin J., May M., et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2002, 20:221-230.
52. Majhail N.S., Weisdorf D.J., Defor T.E., et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:1065-1072.
53. Nademanee A., Molina A., Fung H., et al. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission. Biol Blood Marrow Transplant 1999, 5:292-298.
54. Jabbour E., Hosing C., Ayers G., et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007, 109:2481-2489.
55. Castagna L., Bramanti S., Balzarotti M., et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol 2009, 145:369-372.
56. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. Normalization of FDG-PET Pre-ASCT with additional non-cross resistant chemotherapy improves EFS in patients with relapsed and primary refractory Hodgkin lymphoma-Memorial Sloan Kettering Protocol 04-047. Blood 2008, 112. (abstr 775).
57. Morschhauser F., Brice P., Ferme C., et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM Study Group. J Clin Oncol 2008, 26:5980-5987.
58. Bartlett N., Forero-Torres A., Rosenblatt J., et al. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol 2009, 27. 15s(Suppl) (abstr 8500).
59. Younes A., Fanale M., Pro B., et al. A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol 2007, 25. 18s(Suppl) (abstr 8000).
60. Fehniger T.A., Larson S., Trinkaus K., et al. A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin lymphoma: preliminary results. Blood 2008, 112. (abstr 2595).
61. Mendler J.H., Friedberg J.W. Salvage therapy in Hodgkin's lymphoma. Oncologist 2009, 14:425-432.